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Abstract
Background: The insertion of a Totally Implantable Access Port (TIAP) is a routinely employed
technique in patients who need a safe and permanent venous access. The number of TIAP
implantations is increasing constantly mainly due to advanced treatment options for malignant
diseases. Therefore it is important to identify the implantation technique which has the optimal
benefit/risk ratio for the patient.
Study design: A single-centre, randomized, controlled superiority trial to compare two different
TIAP implantation techniques. Sample size: 160 patients will be included and randomized intra-
operatively. Eligibility criteria: Age equal or older than 18 years, patients scheduled for primary
elective implantation of a TIAP in local anaesthesia and a signed informed consent. Primary
endpoint: Primary success rate of the randomized technique. Intervention: Venae Sectio in
combination with the Seldinger Technique (guide wire and a peel away sheath) will be used to place
a TIAP. Reference treatment: Conventional Venae Sectio will be used with a direct insertion of the
TIAP without guide wire or peel away sheath. Duration of study: Approximately 20 months.
Organisation/Responsibility: The trial will be conducted in compliance with the protocol and
in accordance with the moral, ethical, and scientific principles governing clinical research as set out
in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The trial will also be carried
out in keeping with local and regulatory requirements. The Klinisches Studienzentrum Chirurgie
(KSC) – Centre of Clinical Trials in Surgery at the Department of Surgery, University Hospital
Heidelberg is responsible for planning and conduction of the trial. Documentation of patient's data
will be accomplished via electronical Case Report Files (eCRF) with MACRO®-Software by the
KSC. Randomization, data management, monitoring and biometry are provided by the independent
Koordinierungszentrum für Klinische Studien (KKS) – Coordination Centre for Clinical Trails at
the University of Heidelberg.
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Background
Totally Implantable Access Ports (TIAP)
Insertion of a Totally Implantable Access Port (TIAP) is a
routinely employed technique in patients who need a save
and permanent venous access for e.g. chemotherapy and/
or parenteral nutrition[1]. This system needs no external
dressing, allows the patient normal physical activity, is
probably less prone to infectious complications and will
minimize the occlusion rate of the catheter compared to
non-totally implantable catheters[1]. TIAPs are being
extensively used world-wide and an increase of port place-
ment can be expected with the broader introduction of
innovative therapies in oncology such as the Capri Proto-
col in pancreatic cancer[2].
Implantation techniques
Until today, two alternative approaches to access the cen-
tral venous system are in use: Blind puncture of a central
vein and introduction of a catheter using the Seldinger
Technique or implantation of the TIAP through a surgi-
cally dissected vein (e.g. Venae Sectio of the cephalic vein;
Fig. 1, 2). Both procedures are currently performed by sur-
geons as well as interventional radiologists and have a cer-
tain risk of complications with respect to the applied
technique (pneumothorax, hematothorax, "pinch off"
phenomena i.e. kinking of the catheter, nerve palsy, tho-
racic duct injury)[1,3].
Modified Seldinger Technique (combination of Venae 
Sectio and Seldinger Technique)
The modified Seldinger Technique is a combination of
Venae Sectio and Seldinger Technique using a guide wire
and a peel away sheath in the surgically dissected cephalic
vein. We believe that the usage of the guide wire and peel
away sheath allowes introducting the catheter even in a
small cephalic vein and it offers the possiblity to insert the
catheter beyond obstacles and narrow curves. The advan-
tage of this technique should be the avoidance of the
blind puncture of a central vein (e.g. subclavian vein) and
therefore a lower risk of severe complications like pneu-
mothorax, haematothorax and nerve palsy and the possi-
bility to insert the catheter beyond obstacles or narrow
curves of the cephalic vein (Fig. 3, 4, 5, 6, 7).
Medical problem
Correct placement of the TIAP in the superior Vena Cava
is mandatory for optimal and save usage of the central
venous access. The success rate of TIAP implantation via
the conventional approach by transsection of the cephalic
vein (Venae Sectio) ranges between 70 to 94%[3]. A mul-
tivariate analysis of 400 patients at the Department of Sur-
gery, Universityhospital of Heidelberg, who underwent a
primary port-catheter-system engrafting, showed a success
rate of the conventional approach of 80%[3]. One of the
major causes for failure was an undersized cephalic vein
or an obstacle on the way to the superior Vena Cava[3].
Venae Sectio + Seldinger - Insertion of the guide wire Figure 3
Venae Sectio + Seldinger - Insertion of the guide wire.
Venae Sectio - Incision of V. cephalica Figure 1
Venae Sectio - Incision of V. cephalica.
Venae Sectio - Insertion of the catheter Figure 2
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Furthermore this study showed that the secondary
approach to blind puncture the subclavian vein with
Seldinger Technique achieves an overall success rate of
98% but was also characterized by a number of severe
complications causally related to indirect puncture, like a
pneumo- or hematothorax[1]. In almost all interventional
series using the Seldinger technique, pneumothorax as a
complication occurred (0 to 3.2%)[3]. In contrast a litera-
ture search was not able to identify pneumothorax or
nerve palsy after implantation of a TIAP via Venae Section.
Study design
Aim of study
The objective of this trial is to compare the success and
complication rates of two different implantation tech-
niques for TIAP: Venae Sectio of the cephalic vein and
direct insertion of the port catheter versus Venae Sectio
and insertion of the port catheter with a guide wire and
peel away sheath (modified Seldinger Technique).
Number of patients needed
Two main factors determine the number of patients
needed in a trial. These are the estimated event rate, and
the size of the treatment effect.
Estimated event rate
The multivariate analysis of 400 patients at our Depart-
ment who underwent a TIAP implantation showed a suc-
cess rate of the conventional approach (Venae sectio with
insertion of the catheter without a guide wire) of 80%.
Size of treatment effect that should be detectable
A modification of the conventional approach as described
above must have by surgical decision an expected success
proportion of 0.95[1], if surgical practice should be
changed.
Patients needed
If the real success rate difference is minimum 15% (80%
vs. 95%) then there is a 80% chance that a trial involving
160 patients could detect a significant difference at a level
of 5%.
Eligibility
Inclusion criteria
• Benign and malignant diseases which demand a safe
and permanent venous access, e.g. for chemotherapy and/
or parenteral nutrition
• Age equal or greater than 18 years
• Patients scheduled for primary elective implantation of
a port-catheter-system in local anaesthesia
Venae Sectio + Seldinger - Dilatator removed and catheter  introduced over the guide wire Figure 6
Venae Sectio + Seldinger - Dilatator removed and catheter 
introduced over the guide wire.
Venae Sectio + Seldinger - Insertion of the dilatator and peel  away sheath over the guide wire Figure 4
Venae Sectio + Seldinger - Insertion of the dilatator and peel 
away sheath over the guide wire.
Venae Sectio + Seldinger - Insertion of the dilatator and peel  away sheath over the guide wire Figure 5
Venae Sectio + Seldinger - Insertion of the dilatator and peel 
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• Informed consent
Exclusion criteria
• Participation in another intervention-trial with interfer-
ence of intervention and outcome of this study
• Lack of compliance
• Impaired mental state or language problems (Patient is
not able to read german texts)
Subject withdrawal criteria
• Randomization will be carried out after preparation of
the cephalic vein. If no vein is to exhibit the subject will
be removed from the trial and the pre-rand drop-out is to
record in the CRF
• At their own request or at request of the legal represent-
ative
• If, in the investigator's opinion, continuation of the trial
would be detrimental to the subject's well-being
Consent
Patients who are scheduled for port-catheter-system
implantation will have a pre-treatment visit to give the
informed consent. During this visit the patient will be
screened and informed about the PORTAS trial. In this
conversation with the patient the study procedure, risks,
benefits and data management will be clarified in detail.
Randomization and procedures for minimizing bias
Minimizing systematic bias
In order to achieve comparable groups for known and
unknown risk factors a block randomization will be per-
formed by the randomization software RITA®. A sufficient
number of patients will be recruited according to the sam-
ple seize calculation in order to prevent random error.
Patients will get randomized intra operatively after identi-
fication of the cephalic vein in order to minimize post
randomization drop outs.
Minimizing treatment bias
All physicians who participate in this trial will be trained
and updated every 3 month to guarantee comparable
treatment of patients. Special manuals will be used in
operation theatre to reduce random errors. In addition the
learning curves of the participating surgeons will be
assessed.
Minimizing measurement bias
An independent nurse will document and monitor the
procedure in the operating theatre. Blinding is not possi-
ble and necessary due to the research question.
Study treatment
All patients will be positioned on the table in a five degree
reverse Trendelenburg's position. The neck, chest and
shoulders of the patients will be prepared and draped in
the customary sterile manner. Antibiotic prophylaxis is
only given in patients of risk for endocarditis according to
the local standards. Local anaesthesia will be infiltrated in
sterile fashion into skin and subcutaneous layer and skin
incision will be done 4 cm infer laterally parallel to the
Table 1: Flowchart according to CONSORT
To be assessed for eligibility (n = 280)
Total to be excluded (n = 100)
refusal to participate (n = 40)
not meeting inclusion criteria prior to surgery (n = 20)
no cephalic vein present (n = 20)
other reasons (n = 20)
To be randomized (n = 180)
Experimental Group Control Group
To be allocated to intervention (n = 90)
receive allocated intervention (n = 80)
don't receive allocated intervention (n = 10)
To be allocated to intervention (n = 90)
receive allocated intervention (n = 80)
do not receive allocated intervention (n = 10)
To be analyzed (n = 80) To be analyzed (n = 80)
Venae Sectio + Seldinger - Removing of the peel away sheath Figure 7
Venae Sectio + Seldinger - Removing of the peel away sheath.Trials 2006, 7:20 http://www.trialsjournal.com/content/7/1/20
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clavicle in the deltoid-pectoral region. The cephalic vein is
to exhibit. After exhibition of the cephalic vein the rand-
omization will be performed on a Laptop computer sys-
tem with the RITA® randomization tool.
According to the allocation the procedure will be contin-
ued.
Intervention-group 1
The cephalic vein will be legated distally and encircled cra-
nially with a 3-0 reabsorbable suture. The vein will be
cross-sected ventrally and the catheter flushed with
heparinized saline, introduced. Correct positioning will
be controlled via fluoroscopy (tip of catheter just at aditus
of right atrium) (Fig. 1, 2).
Intervention-group 2
The cephalic vein will be ligated distally and encircled cra-
nially with a 3-0 reabsorb able suture. The vein will be
cross-sected ventrally and a guide wire will be placed
under fluoroscopy to the junction of the superior vena
cava and right atrium. After insertion and correct position-
ing of the wire, a vein dilator and sheath will be passed
over the guide wire. The guide wire and dilator will be
removed, and the catheter will be introduced through the
peel-away sheath. After insertion the peel away sheath will
be removed (Fig. 3, 4, 5, 6, 7).
The catheter will be connected to the port chamber. Using
the same incision, a subcutaneous pocket will be prepared
on the pectoral fascia. The port chamber will be fixed on
the fascia of the pectoral muscle with three single non
absorbable sutures. Flow for blood withdrawal and infu-
sion is tested via cutaneous puncture (Huber needle). To
complete the procedure the system is blocked with isot-
onic saline.
Primary and secondary endpoints
Primary endpoint
The primary endpoint will be the primary success rate of
the randomized implantation technique.
Definition of the primary endpoint
Primary success of the randomized implantation tech-
nique is defined as the correct position of the catheter
checked introperatively by radiography and correct func-
tion checked by drawing blood and injecting isotonic
saline fluid.
Assessment of the primary endpoint
The primary success will be assessed intraoperatively in
the CRF. A copy of the intraoperative radiography will be
recorded in addition.
Secondary endpoints
• Duration of port implantation procedure
• Perioperative complication rate
• Postoperative complication rate
Safety aspects
Specification of safety parameters
Training for surgeons
All surgeons will be briefed and trained in both tech-
niques. The correct placement of the port catheter will be
checked after operation with x-ray and recorded in the
CRF.
Concomitant medication
Concomitant medication will not be recorded because an
interaction between surgical technique and medication of
the patients is unlikely and will therefore not be expected.
This decision was met in total agreement of all involved
study physicians.
Past medical history
Prior and concomitant illness of the patients will be doc-
umented in the CRF because discussions between all
involved study physicians resulted in the opinion that an
interaction between concomitant illness and intervention
will be indeed unlikely but could not completely be
excluded.
Adverse events and serious adverse events
AEs will be reported to the principle investigator in regular
intervals throughout the study. Symptoms anticipated by
Chemotherapy and malignant illness progress and there-
fore unlikely related with the surgical implantation tech-
nique will not be recorded as AE.
SAEs which are meet one of definitions of the secondary
endpoints are treated as SAEs regarding to documentation
but have not to be reported to the sponsor/principle
investigator within 24 h. They will be reported to the prin-
ciple investigator in regular intervals throughout the
study.
Analysis
Comparisons will be made of the primary endpoints of
both intervention groups for all in the study included
patients on an intention to treat basis. Furthermore there
will be a second analysis on a "per protocol" basis includ-
ing only patients who get strictly treated according to the
study protocol. The outcome measures of the primary
endpoint will be tested for significance with the chi square
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Study organization
All patients scheduled for a primary port-catheter-system
implantation procedure in the Outpatient-Clinic of the
Department of Surgery, University Hospital of Heidel-
berg, will be referred to the Centre for Clinical Studies in
Surgery (KSC) and screened by members of the KSC [4].
The result of the screening will be recorded in the screen-
ing-log.
Approximately 500 patients per year undergo a port-cath-
eter-system implantation at the Outpatient-Clinic of the
Department of Surgery, University of Heidelberg. The esti-
mated time frame to randomize 180 patients is approxi-
mately 18 months.
The independent data management and monitoring will
be done by the Coordination Centre for Clinical Trials
(KKS) Heidelberg.
The principal investigator has the right to terminate the
trial and to remove all trial material from the trial centre
at any time in consultation with the Clinical Study Team
Leader and the Biometrician. Reasons that may require a
termination of the trial include the following:
• The incidence or severity of adverse events in this trial
indicates a potential health hazard caused by the study
treatment
• It appears that patient's enrolment is unsatisfactory with
respect to quality and/or quantity or data recording is
severely inaccurate and/or incomplete
• External evidence that makes it necessary to terminate
the trial
Financial support
One half of the costs for this study will be financed by the
Surgical Foundation Heidelberg (Stiftung Chirurgie Hei-
delberg), the other half will be sponsored by Fresenius
Kabi AG ©. This concept of a half-half financial support
will help to guarantee the independency of the final study
analysis and its results from commercial interests.
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